Showing 1971-1980 of 5275 results for "".
- Anti-C5a Antibody Vilobelimab for HS to Be Presented at EADVhttps://practicaldermatology.com/news/anti-c5a-antibody-vilobelimab-hs-be-presented-eadv/2468302/InflaRx N.V. announced the e-poster presentation of a post hoc analysis of the SHINE Phase 2b study of its first-in-class anti-C5a antibody, vilobelimab, in hidradenitis suppurativa (HS) at the 2024 European Academy of Dermatology and Venereology (EADV) Congress being held in Amsterdam, Netherlan
- InnoCare Completes Patient Enrollment in Phase 2 Trial of ICP-488 for the Treatment of Psoriasishttps://practicaldermatology.com/news/innocare-completes-patient-enrollment-phase-2-trial-icp-488-treatment-psoriasis/2463108/InnoCare Pharma announced the completion of patient enrollment for the phase 2 clinical trial of ICP-488, a tyrosine kinase 2 (TYK2) JH2 allosteric inhibitor, for the treatment of psoriasis. The multicenter, randomized, double-blind, placebo-controlled phase 2 study aims to evaluate the e
- Regular Moisturizer Use May Reduce Signs of Aging Skin, Plus More Research from Estée Lauderhttps://practicaldermatology.com/news/regular-moisturizer-use-may-reduce-signs-of-aging-skin-on-the-face-skin-aging-plus-more-wcd-presented-research-from-estee-lauder/2461846/Regular use of moisturizer can mitigate skin aging, according to research presented by The Estée Lauder Companies Inc. at the 25th World Congress of Dermatology in Singapore. In an evaluator-blinded, randomized, 6-month longitudinal study of 160 women, a
- European Commission Approves LEO Pharma’s Adtralza (tralokinumab) for the Treatment of Moderate-to-Severe AD in Adolescentshttps://practicaldermatology.com/news/european-commission-approves-leo-pharmas-adtralza-tralokinumab-for-the-treatment-of-moderate-to-severe-ad-in-adolescents/2461394/The European Commission (EC)e xtended the marketing authorization for LEO Pharma’s Adtralz (tralokinumab) to include adolescents aged 12 to 17 with moderate-to-severe atopic dermatitis (AD) who are candidates for systemic therapy. “Safety is a priority when s
- Amorepacific Introduces the World's First Chip-less Wireless Electronic Skin Enabled by Semiconductorshttps://practicaldermatology.com/news/amorepacific-introduces-the-worlds-first-chip-less-wireless-electronic-skin-enabled-by-semiconductors/2461309/Amorepacific has developed the world's first chip-less wireless wearable electronic skin (e-skin) that is sweatproof and can continuously monitor skin changes over long periods of time. The result follows four years of joint research between Professor Professor&
- FDA Oks Endo's Anti-Cellulite Injectablehttps://practicaldermatology.com/news/fda-oks-endos-anti-cellulite-injectable/2460454/The FDA has given its nod to an entirely new way to address cellulite. Endo Aesthetic’s Qwo (collagenase clostridium histolyticum-aaes) is the first injectable treatment for moderate to severe cellulite of the buttocks in adult women. When fat in cellulite-prone areas swells and e
- Skin Metabolomics: Estee Lauder Presents New Research at WCDhttps://practicaldermatology.com/news/skin-metabolomics-estee-lauder-presents-new-research-at-wcd/2460063/The Estée Lauder Companies Inc.Research & Development (R&D) team will present data focused on new findings in skin metabolomics, skin defense, ingredient science, and anti-aging research at the 2019 World Congress of Dermatology (WCD) in Milan, Italy from June 10 -15.
- PuraCap Pharmaceuticals Introduces EpiCeram Quad Packhttps://practicaldermatology.com/news/puracap-pharmaceuticals-introduces-epiceram-quad-pack/2458088/PuraCap® Pharmaceutical is introducing the EpiCeram® Controlled Release Skin Barrier Emulsion Quad Pack, which contains four 100-gram airless pumps. EpiCeram® is a US Food and Drug Administration-approved topical prescription e
- Pacific Edge Granted US Patent for Melanoma Detectionhttps://practicaldermatology.com/news/20140905-pacific_edge_granted_us_patent_for_melanoma_detection/2459127/The United States Patent and Trademark Office granted Pacific Edge Limited, a cancer diagnostics company, US Patent Number 8,822,149 covering "Prognosis Prediction for Melanoma Cancer." The patent covers the technology being used to develop a melanoma prognostic test that will e
- Clinical Trial Finds New Cream Diminishes Symptoms of Psoriasis, Eczemahttps://practicaldermatology.com/news/20140516-clinical_trial_finds_new_cream_diminishes_symptoms_of_psoriasis_eczema/2459237/Findings from an independent study indicate that the antioxidant-based Psorzema Crème formula from derma e® diminishes symptoms of eczema and psoriasis. In an eight-week study, symptomatic participants used Psorzema® Crème, all of whom showed significant improvement in dryness and flak